Verastem (VSTM) Reports Publication of the Phase 2 DYNAMO Study Results in Indolent Non-Hodgkin Lymphoma in the Journal of Clinical Oncology
Tweet Send to a Friend
Verastem, Inc. (NASDAQ: VSTM) today announced that the results of the Phase 2 DYNAMO™ study, which evaluated COPIKTRA™ (duvelisib) capsules ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
